Christopher Mirabelli Ph.D Overview

  • Primary Position
  • Chairman

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 3

  • Med. Deal Size

  • Med. Valuation

Christopher Mirabelli Ph.D General Information

Biography

Dr. Christopher Mirabelli serves as Chairman at Leap Therapeutics. He also serves as a Independent Advisory Committee member at Longview Healthcare Ventures. He serves as Chairman at Flamingo Therapeutics. He served as Chief Executive Officer and President at DecImmune Therapeutics. He serves as a Board Member at Aro Biotherapeutics. He has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. He has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000, he served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where he had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), where he held several positions including senior vice president of research, from 1989 until 1993. He started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He served as Board Member at Theraclone Sciences and Dynacure and as Managing Director at HealthCare Ventures. He also served as Chief Executive Officer, President and Board Member at Anexon. He was Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999. Before joining Leukosite, he was a co-founder and Executive Vice President of Isis Pharmaceuticals (now Ionis). He was previously with SmithKline and French Laboratories R&D Division. He is a member of the board of advisors of the Accelerator Fund at Harvard Medical School, an initiative that identifies and funds translation of early-stage medical discoveries to preclinical proof-of-concept. He received his Doctor of Philosophy degree in Molecular Pharmacology from Baylor College of Medicine. He served as President & Board Member at Apofore. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. He is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.

Contact Information

Primary Position
Education
Baylor College of Medicine, Ph.D. (Doctor of Philosophy)
State University of New York (SUNY), BS (Bachelor of Science)
Gender
Male
Phone
+1 (617)
Address
  • 47 Thorndike Street
  • Suite B1-1
  • Cambridge, MA 02141
  • United States
+1 (617)

Christopher Mirabelli Ph.D Positions (2)

Firm name Firm type Title Location Industry Since
Flamingo Therapeutics Company Chairman Leuven, Belgium Drug Discovery
HealthCare Ventures Investor Managing Director Cambridge, MA Venture Capital

Christopher Mirabelli Ph.D Board Seats (4)

Company Industry Ownership Status Financing Status Location Since
Aro Biotherapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed Philadelphia, PA
Dynacure Drug Discovery Acquired/Merged Formerly VC-backed France
Flamingo Therapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed Leuven, Belgium
Leap Therapeutics Biotechnology Publicly Held Formerly VC-backed Cambridge, MA

Christopher Mirabelli Ph.D Lead Partner on Deals (23)

Company Deal Date Deal Type Deal Size Deal Status Industry Location
MacroCure 23-Jan-2017 Merger/Acquisition Completed Biotechnology Radnor, PA
Proteostasis Therapeutics 08-Sep-2015 Completed Drug Discovery Boston, MA
Galleon Pharmaceuticals 11-Jun-2015 Completed Pharmaceuticals Horsham, PA
Theraclone Sciences 12-Aug-2013 Completed Drug Delivery Seattle, WA
Trevena 10-May-2013 Completed Drug Discovery Chesterbrook, PA
DecImmune Therapeutics 26-Feb-2013 Completed Drug Discovery Cambridge, MA
Galleon Pharmaceuticals 24-Jan-2012 Completed Pharmaceuticals Horsham, PA
Apofore 01-Aug-2011 Completed Pharmaceuticals Cambridge, MA
Proteostasis Therapeutics 01-Dec-2010 Early Stage VC Completed Drug Discovery Boston, MA
DecImmune Therapeutics 17-Sep-2010 Later Stage VC Completed Drug Discovery Cambridge, MA

Christopher Mirabelli Ph.D Network (204)

Board Members (94)

Name Company Representing Location From
Ohad Hammer Dynacure Pontifax Venture Capital France
Monica Bertagnolli Leap Therapeutics Self Cambridge, MA
Aro Biotherapeutics Self Philadelphia, PA
Dynacure Self France
Flamingo Therapeutics Participatiemaatschappij Vlaanderen Leuven, Belgium

Portfolio Executives (104)

Name Company Role Deal date Location
Michelle Marcelino MacroCure Director, Clinical Operations 23-Jan-2017 Radnor, PA
Uplaksh Kumar Ph.D MacroCure Vice President, Global Operations 23-Jan-2017 Radnor, PA
MacroCure President & Co-Chief Executive Officer 23-Jan-2017 Radnor, PA
MacroCure Co-Chief Executive Officer 23-Jan-2017 Radnor, PA
MacroCure Chief Financial Officer 23-Jan-2017 Radnor, PA

Fund Team Members (6)

Name Investor Fund Fund Location
Douglas Onsi JD HealthCare Ventures HealthCare Ventures VIII Cambridge, MA
Douglas Onsi JD HealthCare Ventures HealthCare Ventures IX Cambridge, MA
HealthCare Ventures Cambridge, MA
HealthCare Ventures Cambridge, MA
HealthCare Ventures Cambridge, MA

Christopher Mirabelli Ph.D Affiliated Funds (3)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
HealthCare Ventures VI HealthCare Ventures Venture - General Fully Invested 2002
HealthCare Ventures VIII HealthCare Ventures Venture - General Closed 2005
HealthCare Ventures IX HealthCare Ventures Venture - General Closed 2010

Christopher Mirabelli Ph.D Advisory Roles (1)

Firm name Firm type Title Location Industry Since
Longview Healthcare Ventures Investor Independent Advisory Committee Member Boston, MA Venture Capital

Christopher Mirabelli Ph.D FAQs

  • Who is Christopher Mirabelli Ph.D?

    Dr. Christopher Mirabelli serves as Chairman at Leap Therapeutics.

  • How much does Christopher Mirabelli Ph.D typically invest?

    Christopher Mirabelli Ph.D's median deal size is .

  • What is Christopher Mirabelli Ph.D’s main position?

    Christopher Mirabelli Ph.D’s primary position is Chairman.

  • How many active board seats does Christopher Mirabelli Ph.D hold?

    Christopher Mirabelli Ph.D holds 4 board seats including Aro Biotherapeutics, Dynacure, Flamingo Therapeutics, and Leap Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »